Bio-Rad Labs (BIO) Announces $250M Stock Buyback

Bio-Rad Laboratories, Inc. (NYSE: BIO) announced that its board of directors has authorized a new share repurchase program, granting the Company authority to repurchase, on a discretionary basis, up to $250 million of the outstanding shares of the Company’s common stock.

“We are pleased that our balance sheet and cash flow enable us to return value to our shareholders through share repurchases as we continue to invest in internal and external opportunities," said Norman Schwartz, Bio-Rad President and CEO. “Earlier this year we discussed our capital allocation approach and a share repurchase program is part of this strategy.”

Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes, including supporting employee stock plans, funding acquisitions and minimizing dilution from stock issuances. This new share repurchase program supersedes the Company’s prior share repurchase program.

You May Also Be Interested In

• Havas repurchases shares under its €50M buyback program
• Cosmos Health posts 29% revenue rise but widens net loss in Q2 2026
• Universal Music Group repurchases 9.4 million shares under €250M buyback